Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Chemotherapy
72%
Neoplasm
70%
Colorectal Carcinoma
51%
Colon Carcinoma
40%
Oxaliplatin
37%
Circulating Tumor DNA
36%
Biological Marker
36%
Progression Free Survival
36%
Bevacizumab
34%
Overall Survival
33%
microRNA 126
31%
microRNA
26%
Rectum Cancer
24%
Capecitabine
20%
Malignant Neoplasm
20%
Epidermal Growth Factor
19%
Lung Cancer
16%
Recurrent Disease
14%
Biliary Tract Cancer
14%
Gamma Interferon
12%
Epidermal Growth Factor Receptor
11%
Diseases
11%
Prostate Cancer
10%
Primary Tumor
10%
Programmed Death 1 Ligand 1
9%
Disseminated Cancer
9%
Panitumumab
9%
Pembrolizumab
9%
Oxaliplatin-Induced Neuropathy
9%
Randomized Controlled Trial
9%
Neuropeptide Y
8%
Vasculotropin A
8%
Clinical Trial
8%
First-Line Chemotherapy
7%
Oxaliplatin-Induced Peripheral Neuropathy
7%
Combination Therapy
7%
Phase II Trials
7%
Prospective Study
7%
Angiogenesis Inhibitor
7%
Gemcitabine
6%
Circulating microRNA
6%
Fluoropyrimidine
5%
Solid Malignant Neoplasm
5%
Non Small Cell Lung Cancer
5%
Immunotherapy
5%
Placebo
5%
Medicine and Dentistry
Colon Carcinoma
83%
Neoplasm
81%
Colorectal Carcinoma
56%
Biological Marker
39%
Rectum Cancer
34%
Metastatic Colorectal Cancer
34%
Malignant Neoplasm
33%
Circulating Tumor DNA
26%
Lung Cancer
24%
Overall Survival
22%
Systematic Review
20%
Recurrent Disease
20%
Stroma
19%
microRNA
18%
Oxaliplatin
17%
microRNA 21
16%
Meta-Analysis
15%
Biliary Tract Cancer
14%
Bevacizumab
14%
Prostate Cancer
14%
DNA Mismatch Repair
14%
Angiogenesis
13%
Progression Free Survival
12%
Capecitabine
12%
Biopsy Technique
11%
Diseases
11%
microRNA 126
11%
Patient-Reported Outcome
10%
Lung
10%
Quality of Life
10%
Hazard Ratio
10%
Arm
10%
Cohort Analysis
10%
Symptomatic Treatment
10%
Chemoradiotherapy
10%
Tumor Infiltrating Lymphocyte
9%
Exon
9%
Drug Megadose
9%
Panitumumab
9%
Pembrolizumab
9%
Lung Tumor
9%
Stereotactic Body Radiation Therapy
9%
Natural Killer Cell
9%
Randomized Controlled Trial
9%
Pancreas Adenocarcinoma
9%
Treatment Response
9%
Metastatic Carcinoma
9%
Oncology
9%
Combination Chemotherapy
8%
Adjuvant Therapy
8%
Biochemistry, Genetics and Molecular Biology
Colon
46%
Circulating Tumor DNA
42%
Overall Survival
40%
MicroRNA
36%
Blood Plasma
32%
Mir-126
24%
Natural Killer Cell
24%
Single-Nucleotide Polymorphism
21%
Progression Free Survival
20%
Bevacizumab
19%
Capecitabine
16%
Vascular Endothelial Growth Factor A
15%
HOXA9
14%
Medline
12%
DNA Methylation
12%
Cohort Study
11%
Recurrence Free Survival
11%
Interferon Gamma
11%
Methylation
11%
Prevalence
10%
Embase
10%
Kinase Insert Domain Receptor
10%
Epidermal Growth Factor Receptor
10%
Disease Free Survival
10%
Epidermal Growth Factor
9%
Growth Factor-Like Domain
9%
Dynamics
9%
Homeobox
9%
Decision Making
9%
Electronic Health Record
9%
Cancer Screening
9%
Droplet Digital Polymerase Chain Reaction
9%
Microsatellite Instability
8%
Genetics
8%
Cell Activity
8%
Web of Science
8%
Real-Time Polymerase Chain Reaction
8%
Clinical Trial
7%
KRAS
7%
Cancer Mortality
7%
Gene Expression Profiling
6%
Eosin
6%
Cancer Cell
6%
Angiogenesis
6%
Computer Assisted Tomography
5%
Cochrane Library
5%
Enzyme
5%
Vascular Endothelial Growth Factor
5%
Microsatellite
5%
RNA
5%
